Article
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
Annals of internal medicine - 7 Jul 2015
Zeuzem Stefan, Ghalib Reem, Reddy K Rajender, Pockros Paul J, Ben Ari Ziv, Zhao Yue, Brown Deborah D, Wan Shuyan, DiNubile Mark J, Nguyen Bach-Yen, Robertson Michael N, Wahl Janice, Barr Eliav, Butterton Joan R
Abstract excerpt
BACKGROUND: Novel interferon- and ribavirin-free regimens are needed to treat hepatitis C virus (HCV) infection. OBJECTIVE: To evaluate the safety and efficacy of grazoprevir (NS3/4A protease inhibitor) and elbasvir (NS5A inhibitor) in treatment-naive patients. DESIGN: Randomized, blinded, placebo-controlled trial. (ClinicalTrials.gov: NCT02105467). SETTING: 60 centers in the United States, Europe, Australia,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.